Business Context and Reporting Period
This Form 8-K is filed by Mind Medicine (MindMed) Inc. (MNMD), a British Columbia, Canada corporation, on March 28, 2022. The filing primarily addresses the announcement of financial results for the fiscal year ended December 31, 2021, and a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the fiscal year ended December 31, 2021. However, this specific 8-K text does not provide numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial data.
Material Changes and Accounting Firm Transition
- Dismissal of EY: The Board of Directors determined not to reappoint Ernst & Young (Canada) LLP (EY) as the principal accountant for the fiscal year ending December 31, 2022.
- Material Weakness Identified: During the preparation of the 2021 consolidated financial statements, EY identified a material weakness in internal controls over financial reporting related to the accounting for contracts. This was discussed with the Audit Committee.
- Appointment of KPMG: The Board approved the engagement of KPMG LLP as the new independent registered public accounting firm for the year ending December 31, 2022, subject to shareholder approval at the 2022 annual meeting.
- Audit History: EY's reports for the periods ended December 31, 2021, and 2020 contained no adverse opinions, disclaimers, or qualifications. There were no disagreements with EY regarding accounting principles or practices.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosed material weakness in internal controls. The change in auditors is contingent upon shareholder approval at the upcoming annual meeting.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2021 financial results (revenue, net loss, cash position).
- Verify the details of the material weakness in internal controls regarding contract accounting and the remediation plan.
- Confirm the outcome of the shareholder vote on the appointment of KPMG LLP at the 2022 annual meeting.
- Monitor future filings for any further disclosures regarding the transition between EY and KPMG.